Skip to main content
. Author manuscript; available in PMC: 2017 Aug 31.
Published in final edited form as: Adv Drug Deliv Rev. 2017 Jun 10;113:177–200. doi: 10.1016/j.addr.2017.06.002

Figure 6.

Figure 6

Schematic illustration of differential diagnosis of brain tumors by MRI using systemically administered Gd-conjugated polymeric nano imaging agents. Mice had different tumors grown in each hemisphere, an EGFR+ glioblastoma and HER2+ breast cancer. Using BBB-permeating and HER2-targeted PMLA-based nano imaging agent it is possible to noninvasively diagnose by MRI the HER2+ tumor (it is the only one visible), which can be subsequently treated with a similar nano agent (see Fig. 8). This is not possible with a standard MRI agent MultiHance that highlights both tumors. Reproduced from [14].